US3655679A
(en)
|
1969-06-25 |
1972-04-11 |
Merck & Co Inc |
Certain aryl pyridine carboxylic acid derivatives
|
US3703582A
(en)
|
1970-04-20 |
1972-11-21 |
Merck & Co Inc |
Aryl pyridine carboxylic acids in the treatment of inflammation
|
US3894920A
(en)
|
1971-12-21 |
1975-07-15 |
Sagami Chem Res |
Process for preparing alkyl-substituted 3,6-dihydro-o-dioxin derivatives
|
US4016287A
(en)
|
1972-07-17 |
1977-04-05 |
Boehringer Ingelheim Gmbh |
Dermatological compositions containing an acylamino-carboxylic acid or an alkyl ester thereof
|
TW219933B
(es)
|
1990-02-26 |
1994-02-01 |
Lilly Co Eli |
|
US5405613A
(en)
|
1991-12-11 |
1995-04-11 |
Creative Nutrition Canada Corp. |
Vitamin/mineral composition
|
TW352384B
(en)
|
1992-03-24 |
1999-02-11 |
Hoechst Ag |
Sulfonamido- or sulfonamidocarbonylpyridine-2-carboxamides, process for their preparation and their use as pharmaceuticals
|
DE4219158A1
(de)
|
1992-06-11 |
1993-12-16 |
Thomae Gmbh Dr K |
Biphenylderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
|
ES2101420T3
(es)
|
1993-11-02 |
1997-07-01 |
Hoechst Ag |
Esteres-amidas de acidos carboxilicos heterociclicos sustituidos, su preparacion y su utilizacion como medicamentos.
|
DK0650961T3
(da)
|
1993-11-02 |
1997-09-15 |
Hoechst Ag |
Substituerede heterocykliske carboxylsyreamider, deres fremstilling og deres anvendelse som lægemidler.
|
TW406076B
(en)
|
1993-12-30 |
2000-09-21 |
Hoechst Ag |
Substituted heterocyclic carboxamides, their preparation and their use as pharmaceuticals
|
DE4410423A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureamide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
DE4410480A1
(de)
|
1994-03-25 |
1995-09-28 |
Hoechst Ag |
Sulfonamidocarbonylpyridin-2-carbonsäureesteramide sowie ihre Pyridin-N-oxide, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
US5789426A
(en)
|
1995-01-20 |
1998-08-04 |
Cornell Research Foundation, Inc. |
Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation
|
IL135495A
(en)
|
1995-09-28 |
2002-12-01 |
Hoechst Ag |
Intermediate compounds for the preparation of quinoline-converted amines - 2 - carboxylic acid
|
JPH09221476A
(ja)
|
1995-12-15 |
1997-08-26 |
Otsuka Pharmaceut Co Ltd |
医薬組成物
|
WO1997041103A1
(de)
|
1996-04-30 |
1997-11-06 |
Hoechst Aktiengesellschaft |
3-alkoxypyridin-2-carbonsäureamidester, ihre herstellung und ihre verwendung als arzneimittel
|
DE19620041A1
(de)
|
1996-05-17 |
1998-01-29 |
Merck Patent Gmbh |
Adhäsionsrezeptor-Antagonisten
|
DE19650215A1
(de)
|
1996-12-04 |
1998-06-10 |
Hoechst Ag |
3-Hydroxypyridin-2-carbonsäureamidester, ihre Herstellung und ihre Verwendung als Arzneimittel
|
EP1024134A4
(en)
|
1997-10-09 |
2003-05-14 |
Ono Pharmaceutical Co |
DERIVATIVES OF AMINOBUTANIC ACID
|
DE19746287A1
(de)
|
1997-10-20 |
1999-04-22 |
Hoechst Marion Roussel De Gmbh |
Substituierte Isochinolin-2-Carbonsäureamide, ihre Herstellung und ihre Verwendung als Arzneimittel
|
DE69919349T2
(de)
|
1998-03-23 |
2005-01-13 |
Aventis Pharmaceuticals Inc. |
Piperidinyl- und n-amidinopiperidinyl-derivate
|
US6159379A
(en)
|
1999-05-04 |
2000-12-12 |
Baker Hughes Incorporated |
Organic ammonium salts for the removal of water soluble organics in produced water
|
JP2001048786A
(ja)
|
1999-08-05 |
2001-02-20 |
Yamanouchi Pharmaceut Co Ltd |
三環式ヘテロアリール誘導体
|
US6589758B1
(en)
|
2000-05-19 |
2003-07-08 |
Amgen Inc. |
Crystal of a kinase-ligand complex and methods of use
|
US6855510B2
(en)
|
2001-03-20 |
2005-02-15 |
Dana Farber Cancer Institute, Inc. |
Pharmaceuticals and methods for treating hypoxia and screening methods therefor
|
US6849718B2
(en)
|
2001-03-20 |
2005-02-01 |
Dana Farber Cancer Institute, Inc. |
Muteins of hypoxia inducible factor alpha and methods of use thereof
|
AU2002241154A1
(en)
|
2001-03-21 |
2002-10-03 |
Isis Innovation Ltd. |
Assays, methods and means relating to hypoxia inducible factor (hif) hydroxylase
|
SE0101327D0
(sv)
|
2001-04-12 |
2001-04-12 |
Astrazeneca Ab |
New crystalline forms
|
US6566088B1
(en)
|
2001-10-04 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Prolyl-4-hydroxylases
|
GB0124941D0
(en)
|
2001-10-17 |
2001-12-05 |
Glaxo Group Ltd |
Chemical compounds
|
US20030153503A1
(en)
|
2001-12-06 |
2003-08-14 |
Klaus Stephen J. |
Methods of increasing endogenous erythropoietin (EPO)
|
MXPA04011310A
(es)
|
2002-05-17 |
2005-02-14 |
Celgene Corp |
Metodo y composiciones que utilizan farmacos inhibidores selectivos de citocinas para el tratamiento y el manejo de canceres y otras enfermedades.
|
US7163951B2
(en)
|
2002-08-29 |
2007-01-16 |
Merck & Co., Inc. |
N-biarylmethyl aminocycloalkanecarboxamide derivatives
|
ATE452204T1
(de)
|
2002-10-16 |
2010-01-15 |
Isis Innovation |
Screening-methoden unter verwendung eines strukturmodells von fih
|
JP2006522735A
(ja)
|
2002-11-21 |
2006-10-05 |
イーライ リリー アンド カンパニー |
ミックス系統キナーゼモジュレータ
|
US8124582B2
(en)
|
2002-12-06 |
2012-02-28 |
Fibrogen, Inc. |
Treatment of diabetes
|
US7618940B2
(en)
|
2002-12-06 |
2009-11-17 |
Fibrogen, Inc. |
Fat regulation
|
US7183287B2
(en)
|
2003-04-03 |
2007-02-27 |
Pharmacia Corporation |
Substituted pyrimidinones
|
US8614204B2
(en)
|
2003-06-06 |
2013-12-24 |
Fibrogen, Inc. |
Enhanced erythropoiesis and iron metabolism
|
PT1644336E
(pt)
|
2003-06-06 |
2011-04-21 |
Fibrogen Inc |
Compostos de heteroarilo que contêm azoto e sua utilização no aumento da eritropoetina endógena
|
US20060251638A1
(en)
|
2003-06-06 |
2006-11-09 |
Volkmar Guenzler-Pukall |
Cytoprotection through the use of hif hydroxylase inhibitors
|
GB0314129D0
(en)
|
2003-06-18 |
2003-07-23 |
Astrazeneca Ab |
Therapeutic agents
|
JPWO2005108370A1
(ja)
|
2004-04-16 |
2008-03-21 |
味の素株式会社 |
ベンゼン化合物
|
NZ551632A
(en)
|
2004-05-28 |
2009-09-25 |
Fibrogen Inc |
HIF prolyl hydroxylase activity assay
|
WO2005115984A2
(en)
|
2004-05-31 |
2005-12-08 |
Tanabe Seiyaku Co., Ltd. |
Large conductance calcium-activitated k channel opener
|
KR20070083484A
(ko)
|
2004-07-14 |
2007-08-24 |
피티씨 테라퓨틱스, 인크. |
C형 간염 치료 방법
|
TW200616969A
(en)
|
2004-09-17 |
2006-06-01 |
Tanabe Seiyaku Co |
Imidazole compound
|
WO2006084210A2
(en)
|
2005-02-04 |
2006-08-10 |
Regents Of The University Of California, San Diego |
Hif modulating compounds and methods of use thereof
|
DE102005019712A1
(de)
|
2005-04-28 |
2006-11-09 |
Bayer Healthcare Ag |
Dipyridyl-dihydropyrazolone und ihre Verwendung
|
AU2006254897A1
(en)
|
2005-06-06 |
2006-12-14 |
Fibrogen, Inc. |
Improved treatment for anemia using a HIF-alpha stabilising agent
|
MX2007016160A
(es)
|
2005-06-15 |
2008-03-07 |
Fibrogen Inc |
Uso de moduladoers de hif-1 alfa para el tratamiento contra el cancer.
|
WO2007033216A2
(en)
|
2005-09-12 |
2007-03-22 |
Beth Israel Deaconess Medical Center |
Methods and compositions for the treatment and diagnosis of diseases characterized by vascular leak, hypotension, or a procoagulant state
|
WO2007038571A2
(en)
|
2005-09-26 |
2007-04-05 |
Smithkline Beecham Corporation |
Prolyl hydroxylase antagonists
|
WO2007047194A2
(en)
|
2005-10-11 |
2007-04-26 |
Dana-Farber Cancer Institute, Inc. |
Methods for treating mitf-related disorders
|
JP5202327B2
(ja)
|
2005-12-09 |
2013-06-05 |
アムジエン・インコーポレーテツド |
プロリルヒドロキシラーゼ阻害活性を示すキノロンベースの化合物、およびこの組成物、およびこの使用
|
BRPI0706377A2
(pt)
|
2006-01-09 |
2011-03-22 |
Btg Int Ltd |
moduladores de fator -1 induzìvel por hipoxia e usos relacionados
|
EP1983823A1
(en)
|
2006-01-17 |
2008-10-29 |
VIB vzw |
Inhibitors of prolyl-hydroxylase 1 for the treatment of skeletal muscle degeneration
|
JP4801451B2
(ja)
|
2006-01-19 |
2011-10-26 |
株式会社日立ハイテクノロジーズ |
走査電子顕微鏡等に用いる電子銃の制御装置及び制御方法
|
EP1979353A2
(en)
|
2006-01-19 |
2008-10-15 |
OSI Pharmaceuticals, Inc. |
Fused heterobicyclic kinase inhibitors
|
ITMI20060179A1
(it)
|
2006-02-02 |
2007-08-03 |
Abiogen Pharma Spa |
Procedimento per la risoluzione di miscele racemiche e complesso diastereoisomerico di un agente risolvente e di unantiomero di interesse
|
US7625927B2
(en)
|
2006-02-27 |
2009-12-01 |
Alcon Research, Ltd. |
Method of treating glaucoma
|
PE20071020A1
(es)
|
2006-03-07 |
2007-12-11 |
Smithkline Beecham Corp |
Compuestos derivados de glicina n-sustituidos como inhibidores de prolil hidroxilasa
|
US7588924B2
(en)
|
2006-03-07 |
2009-09-15 |
Procter & Gamble Company |
Crystal of hypoxia inducible factor 1 alpha prolyl hydroxylase
|
JP2009537558A
(ja)
|
2006-05-16 |
2009-10-29 |
スミスクライン・ビーチャム・コーポレイション |
プロリルヒドロキシラーゼ阻害剤
|
TWI394747B
(zh)
|
2006-06-23 |
2013-05-01 |
Smithkline Beecham Corp |
脯胺醯基羥化酶抑制劑
|
EP4095127A1
(en)
|
2006-06-26 |
2022-11-30 |
Akebia Therapeutics Inc. |
Prolyl hydroxylase inhibitors and methods of use
|
CL2008000066A1
(es)
|
2007-01-12 |
2008-08-01 |
Smithkline Beecham Corp |
Compuestos derivados de (5-hidroxi-3-oxo-2,3-dihidropiridazina-4-carbonil)glicina, inhibidores de hif prolil hidroxilasas; procedimiento de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anem
|
CL2008000065A1
(es)
|
2007-01-12 |
2008-09-22 |
Smithkline Beecham Corp |
Compuestos derivados de glicina n-sustituida, inhibidores de hif prolil hidroxilasas; su proceso de preparacion; composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de la anemia.
|
AU2008241577B2
(en)
|
2007-04-18 |
2011-04-07 |
Amgen Inc. |
Indanone derivatives that inhibit prolyl hydroxylase
|
AU2008241503A1
(en)
|
2007-04-18 |
2008-10-30 |
Merck Sharp & Dohme Corp. |
Novel 1,8-naphthyridine compounds
|
WO2008137060A1
(en)
|
2007-05-04 |
2008-11-13 |
Amgen Inc. |
Thienopyridine and thiazolopyridine derivatives that inhibit prolyl hydroxylase activity
|
JP5349462B2
(ja)
|
2007-05-16 |
2013-11-20 |
メルク・シャープ・アンド・ドーム・コーポレーション |
スピロインダロン
|
US8796253B2
(en)
|
2007-05-18 |
2014-08-05 |
Bayer Intellectual Property Gmbh |
Heteroaryl substituted pyrazole derivatives useful for treating hyper-proliferative disorders and diseases associated with angiogenesis
|
CN101868251B
(zh)
|
2007-08-06 |
2012-10-10 |
千寿制药株式会社 |
含有HIF-1α和HIF-2α表达抑制物质的药物
|
TW200908984A
(en)
|
2007-08-07 |
2009-03-01 |
Piramal Life Sciences Ltd |
Pyridyl derivatives, their preparation and use
|
EP2188295A4
(en)
|
2007-08-10 |
2011-11-16 |
Crystalgenomics Inc |
PYRIDINE DERIVATIVES AND METHODS OF USE
|
WO2009035534A2
(en)
|
2007-09-07 |
2009-03-19 |
The Cleveland Clinic Foundation |
Treatment of ischemic eye disease by the systematic pharmaceutical activation of hypoxia inducible factor (hif)
|
WO2009039321A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009039323A1
(en)
|
2007-09-19 |
2009-03-26 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009043093A1
(en)
|
2007-10-04 |
2009-04-09 |
Newsouth Innovations Pty Limited |
Hif inhibition
|
WO2009049112A1
(en)
|
2007-10-10 |
2009-04-16 |
Smithkline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009067790A1
(en)
|
2007-11-26 |
2009-06-04 |
Uti Limited Partnership |
STIMULATION OF HYPOXIA INDUCIBLE FACTOR -1 ALPHA (HIF-1α) FOR THE TREATMENT OF CLOSTRIDIUM DIFFICILE ASSOCIATED DISEASE (CDAD), FOR INTESTINAL MOTILITY AND FOR DETECTING INFECTION
|
JP2011505367A
(ja)
|
2007-11-30 |
2011-02-24 |
グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー |
プロリルヒドロキシラーゼ阻害剤
|
US20100305133A1
(en)
|
2007-11-30 |
2010-12-02 |
Smithkline Beecham Corporation |
Prolyl Hydroxylase Inhibitors
|
WO2009073669A1
(en)
|
2007-12-03 |
2009-06-11 |
Fibrogen, Inc. |
Isoxazolopyridine derivatives for use in the treatment of hif-mediated conditions
|
WO2009086044A1
(en)
|
2007-12-19 |
2009-07-09 |
Smith Kline Beecham Corporation |
Prolyl hydroxylase inhibitors
|
WO2009086592A1
(en)
|
2008-01-04 |
2009-07-16 |
Garvan Institute Of Medical Research |
Method of increasing metabolism
|
WO2009089547A1
(en)
|
2008-01-11 |
2009-07-16 |
Fibrogen, Inc. |
Isothiazole-pyridine derivatives as modulators of hif (hypoxia inducible factor) activity
|
PT2268618E
(pt)
|
2008-03-03 |
2015-10-12 |
Novartis Ag |
Compostos e composições moduladores da actividade tlr
|
EP2268143A4
(en)
|
2008-03-20 |
2012-06-27 |
Forest Lab Holdings Ltd |
NEW PIPERIDINE DERIVATIVES AS INHIBITORS OF THE STEAROYL COA DESATURASE
|
AR071997A1
(es)
|
2008-06-04 |
2010-07-28 |
Bristol Myers Squibb Co |
Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
|
KR20110033291A
(ko)
|
2008-07-23 |
2011-03-30 |
에프. 호프만-라 로슈 아게 |
헤테로사이클릭 항바이러스 화합물
|
KR20110063537A
(ko)
|
2008-09-15 |
2011-06-10 |
카시나 라일라 이노바 파마슈티칼스 프라이빗 리미티드 |
전이성 악성 흑색종 및 기타 암에 대한 항암 약물 및 이와 관련한 용도
|
CN102272117B
(zh)
|
2008-11-14 |
2015-06-17 |
菲布罗根有限公司 |
作为hif羟化酶抑制剂的苯并噻喃衍生物
|
WO2010128355A2
(en)
*
|
2008-12-26 |
2010-11-11 |
Actavis Group Ptc Ehf |
Improved processes for preparing substantially pure arformoterol and its intermediates
|
PT2415771E
(pt)
|
2009-03-31 |
2013-10-03 |
Kissei Pharmaceutical |
Derivado de indolizina e sua utilização para fins médicos
|
MX2012005275A
(es)
|
2009-11-06 |
2012-06-19 |
Aerpio Therapeutics Inc |
Composiciones y metodos para tratar colitis.
|
NO2686520T3
(es)
|
2011-06-06 |
2018-03-17 |
|
|
MX2013014310A
(es)
|
2011-06-06 |
2014-01-23 |
Akebia Therapeutics Inc |
Compuestos y composiciones para estabilizar el factor-2 alfa inducible por hipoxia como un metodo para tratar el cancer.
|
US20130022974A1
(en)
|
2011-06-17 |
2013-01-24 |
The Regents Of The University Of Michigan |
Dna methylation profiles in cancer
|
US9206134B2
(en)
|
2011-07-22 |
2015-12-08 |
Beijing Betta Pharmaceuticals Co. Ltd. |
Polymorphic forms of compounds as prolyl hydroxylase inhibitor, and uses thereof
|
EP2983674A4
(en)
|
2013-04-08 |
2017-05-10 |
Dennis M. Brown |
Therapeutic benefit of suboptimally administered chemical compounds
|
LT3007695T
(lt)
|
2013-06-13 |
2024-03-25 |
Akebia Therapeutics, Inc. |
Kompozicijos ir būdai, skirti anemijos gydymui
|
CN105979779A
(zh)
|
2013-08-16 |
2016-09-28 |
俄亥俄州国家创新基金会 |
调整dna甲基化的组合物和方法
|
US9701636B2
(en)
|
2013-11-15 |
2017-07-11 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino}acetic acid, compositions, and uses thereof
|
MX2016009331A
(es)
|
2014-01-23 |
2016-10-26 |
Akebia Therapeutics Inc |
Composiciones y metodos para tratar enfermedades oculares.
|
WO2016109300A1
(en)
*
|
2014-12-30 |
2016-07-07 |
Dow Agrosciences Llc |
Picolinamides with fungicidal activity
|
EP3247355A4
(en)
|
2015-01-23 |
2018-06-13 |
Akebia Therapeutics, Inc. |
Solid forms of 2-(5-(3-fluorophenyl)-3-hydroxypicolinamido)acetic acid, compositions, and uses thereof
|
WO2016153996A1
(en)
|
2015-03-20 |
2016-09-29 |
Akebia Therapeutics, Inc. |
Deuterium-enriched hypoxia-inducible factor prolyl hydroxylase enzyme inhibitors
|
CN106146491B
(zh)
*
|
2015-03-27 |
2017-12-12 |
沈阳三生制药有限责任公司 |
被芳基或杂芳基取代的5‑羟基‑1,7‑萘啶化合物、其制备方法及其制药用途
|
PE20180189A1
(es)
|
2015-04-01 |
2018-01-23 |
Akebia Therapeutics Inc |
Composiciones y metodos para el tratamiento de la anemia
|
CN105837502A
(zh)
*
|
2016-04-05 |
2016-08-10 |
湖南欧亚生物有限公司 |
一种Vadadustat的合成方法
|
TW202406895A
(zh)
|
2018-05-09 |
2024-02-16 |
美商阿克比治療有限公司 |
用於製備2-[[5-(3-氯苯基)-3-羥基吡啶-2-羰基]胺基]乙酸之方法
|
CN111320577B
(zh)
|
2018-12-13 |
2023-06-23 |
广东东阳光药业有限公司 |
一种吡啶酰胺的制备方法及其应用
|
AU2020374963A1
(en)
|
2019-10-31 |
2022-06-09 |
Akebia Therapeutics, Inc. |
Therapeutic methods using vadadustat
|
US11524939B2
(en)
|
2019-11-13 |
2022-12-13 |
Akebia Therapeutics, Inc. |
Solid forms of {[5-(3-chlorophenyl)-3-hydroxypyridine-2-carbonyl]amino} acetic acid
|
EP4121426A1
(en)
|
2020-03-20 |
2023-01-25 |
Akebia Therapeutics Inc. |
Phd inhibitor compounds, compositions, and use
|
CA3176140A1
(en)
|
2020-03-20 |
2021-09-23 |
Akebia Therapeutics, Inc. |
Phd inhibitor compounds, compositions, and use
|
CN115605467A
(zh)
|
2020-03-20 |
2023-01-13 |
阿克比治疗有限公司(Us) |
Phd抑制剂化合物、组合物和其用途
|